Yıl: 2021 Cilt: 32 Sayı: 3 Sayfa Aralığı: 269 - 275 Metin Dili: İngilizce DOI: 10.5152/tjg.2021.20210 İndeks Tarihi: 26-05-2022

Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change

Öz:
Background: It is known that clarithromycin resistance has increased over the years (success rate 60%). The aim of the study was to investigate the importance of regional antimicrobial resistance rates for full accuracy of both diagnosis and treatment of Helicobacter pylori infection. Methods: This study was carried out in the University Hospital Department of Gastroenterology. A total of 116 patients were evaluated with upper gastrointestinal endoscopy. Gastric antrum and corpus biopsy samples were taken for the rapid urease test (RUT), culture, and antimicrobial susceptibility testing for the presence of H. pylori. Antimicrobial susceptibilities of isolated H. pylori strains for clarithromycin and levofloxacin were determined by the epsilometer test (E-test). Minimal inhibitory concentration values for clarithromycin and levofloxacin were ≥1 and >1 µg/mL, respectively. Results: H. pylori infection was considered clinically positive in 93 (80.2%) patients with either the RUT, culture, or histopathological examination. Seventy (60.3%) of the patients had RUT positivity. Sixty (85.7%) of these 70 patients had RUT positivity within the first 20 min. Among the 90 patients, who had a histopathological examination, HLO was positive in 76 (84.4%) patients. Fifty-two (44.8%) out of 116 patients were culture positive. Resistance rates for both clarithromycin and levofloxacin were high. In these 52 culture-positive patients, resistance rates determined for clarithromycin and levofloxacin were 26.9% and 25.5%, respectively. Conclusion: Clarithromycin or levofloxacin-based treatment regimen may not be an ideal alternative therapy for Turkish patients regardless of culture.
Anahtar Kelime: H. pylori clarithromycin levofloxacin culture susceptibility diagnosis

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772–781. [CrossRef]
  • 2. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, crosssectional, screening with the ¹³C-Urea breath test. BMC Public Health. 2013;13:1215. [CrossRef]
  • 3. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report Gut 2017. Gut. 2017;66(1):6–30. [CrossRef]
  • 4. Crowe SE. Helicobacter pylori infection. N Engl J Med. 2019;380(12):1158–1165. [CrossRef]
  • 5. Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: current status and rational treatment options. North Clin Istanb. 2019;7(1):87–94. [CrossRef]
  • 6. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sdyney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–1181. [CrossRef]
  • 7. Osato MS. Antimicrobial susceptibility testing for Helicobacter pylori: sensitivity test results and their clinical relevance. Curr Pharm Des. 2000;6(15):1545–1555. [CrossRef]
  • 8. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents. 2006;28(1):6–13. [CrossRef]
  • 9. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother. 2007;51(1):346–349. [CrossRef]
  • 10. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 2009;14(1):61–65. [CrossRef]
  • 11. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother. 2005;56(5):965–967. [CrossRef]
  • 12. Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of H. pylori in Turkey: a systematic review. Helicobacter. 2016;21(4):251–260. [CrossRef]
  • 13. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34–42. [CrossRef] 14. Savoldi A, Carrara E, Graham DY, Conti M, Tacco nelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions.
  • Gastroenterology. 2018;155(5):1372.e17–1382.e17. [CrossRef] 15. Unler GK, Teke Ozgur G, Gokturk HS, Karakoca A, Erinanc OH. A comparison of five different treatment regimens as the first-line treatment of Helicobacter pylori in Turkey. Helicobacter. 2016;21(4):279–285. [CrossRef]
  • 16. Erkut M, Uzun DY, Kaklıkkaya N, et al. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the eastern Black Sea region of Turkey. Turk J Gastroenterol. 2020;31(3):221–233. [CrossRef]
  • 17. Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015;48(3):278–284. [CrossRef]
  • 18. Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol. 2007;41(8):747–750. [CrossRef]
  • 19. Ermis F, Tasci S, E. Current Helicobacter pylori treatment in 2014. World J Methodol. 2015;5(2):101–107. [CrossRef]
  • 20. Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol.
  • 2019;30(5):420–435. [CrossRef]
  • 21. Rakici H, Ayaz T, Akdogan RA, Bedir R. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. Digestion. 2014;90(4):261–264. [CrossRef]
  • 22. Erçin CN, Uygun A, Toros AB, et al. Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. Turk J Gastroenterol. 2010;21(1):12–16. [CrossRef]
  • 23. Chung JW, Lee GH, Jeong JY, et al. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol. 2012;27(3):493–497. [CrossRef]
  • 24. Lee JW, Kim N, Nam RH, et al. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter. 2011;16(4):301–310. [CrossRef]
  • 25. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010;8(1):59–70. [CrossRef]
  • 26. McNicholl AG, Ducons J, Barrio J, et al. Accuracy of the ultra-rapid urease test for diagnosis of Helicobacter pylori infection. Gastroenterol Hepatol N Y. 2017;40(10):651–657. [CrossRef]
  • 27. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of Helicobacter pylori infection: current options and developments. World J Gastroenterol. 2015;21(40):11221–11235. [CrossRef]
  • 28. Sabbagh P, Mohammadnia-Afrouzi M, Javanian M, et al. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis. 2019;38(1):55–66. [CrossRef]
  • 29. Fiorini G, Zullo A, Saracino IM, Pavoni M, Vaira D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016. Scand J Gastroenterol. 2018;53(6):661–664. [CrossRef]
  • 30. Park JY, Dunbar KB, Mitui M, et al. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig Dis Sci. 2016;61(8):2373–2380. [CrossRef]
APA Gokcekuyu B, Yılmaz Ö, Soyturk M, Ellidokuz H, Akpınar H, simsek i (2021). Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. , 269 - 275. 10.5152/tjg.2021.20210
Chicago Gokcekuyu Bilge Muge,Yılmaz Özlem,Soyturk Mujde,Ellidokuz Hülya,Akpınar Hale,simsek ilkay Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. (2021): 269 - 275. 10.5152/tjg.2021.20210
MLA Gokcekuyu Bilge Muge,Yılmaz Özlem,Soyturk Mujde,Ellidokuz Hülya,Akpınar Hale,simsek ilkay Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. , 2021, ss.269 - 275. 10.5152/tjg.2021.20210
AMA Gokcekuyu B,Yılmaz Ö,Soyturk M,Ellidokuz H,Akpınar H,simsek i Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. . 2021; 269 - 275. 10.5152/tjg.2021.20210
Vancouver Gokcekuyu B,Yılmaz Ö,Soyturk M,Ellidokuz H,Akpınar H,simsek i Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. . 2021; 269 - 275. 10.5152/tjg.2021.20210
IEEE Gokcekuyu B,Yılmaz Ö,Soyturk M,Ellidokuz H,Akpınar H,simsek i "Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change." , ss.269 - 275, 2021. 10.5152/tjg.2021.20210
ISNAD Gokcekuyu, Bilge Muge vd. "Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change". (2021), 269-275. https://doi.org/10.5152/tjg.2021.20210
APA Gokcekuyu B, Yılmaz Ö, Soyturk M, Ellidokuz H, Akpınar H, simsek i (2021). Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. Turkish Journal of Gastroenterology, 32(3), 269 - 275. 10.5152/tjg.2021.20210
Chicago Gokcekuyu Bilge Muge,Yılmaz Özlem,Soyturk Mujde,Ellidokuz Hülya,Akpınar Hale,simsek ilkay Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. Turkish Journal of Gastroenterology 32, no.3 (2021): 269 - 275. 10.5152/tjg.2021.20210
MLA Gokcekuyu Bilge Muge,Yılmaz Özlem,Soyturk Mujde,Ellidokuz Hülya,Akpınar Hale,simsek ilkay Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. Turkish Journal of Gastroenterology, vol.32, no.3, 2021, ss.269 - 275. 10.5152/tjg.2021.20210
AMA Gokcekuyu B,Yılmaz Ö,Soyturk M,Ellidokuz H,Akpınar H,simsek i Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. Turkish Journal of Gastroenterology. 2021; 32(3): 269 - 275. 10.5152/tjg.2021.20210
Vancouver Gokcekuyu B,Yılmaz Ö,Soyturk M,Ellidokuz H,Akpınar H,simsek i Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change. Turkish Journal of Gastroenterology. 2021; 32(3): 269 - 275. 10.5152/tjg.2021.20210
IEEE Gokcekuyu B,Yılmaz Ö,Soyturk M,Ellidokuz H,Akpınar H,simsek i "Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change." Turkish Journal of Gastroenterology, 32, ss.269 - 275, 2021. 10.5152/tjg.2021.20210
ISNAD Gokcekuyu, Bilge Muge vd. "Unacceptable Antibiotic Resistance Rates for Helicobacter pylori in Turkey: Something Must Change". Turkish Journal of Gastroenterology 32/3 (2021), 269-275. https://doi.org/10.5152/tjg.2021.20210